Zepp Health is currently navigating a challenging strategic pivot toward self-branded wearables, evidenced by a 38.1% year-over-year revenue growth in 2025Q4 that remains undermined by structural operating losses.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 1, 2026 | -$0.79 vs — | $64M-0.6% vs $64M |
Q3 2026 Jun 9, 2026 | -$1.13 vs — | $39M vs — |
Q3 2026 Jun 8, 2026 | -$1.13 vs — | $39M vs — |
Q2 2026 Mar 16, 2026 | -$0.40 vs — | $85M vs — |
Zepp Health (NYSE: ZEPP - Get Free Report) and Bassett Furniture Industries (NASDAQ: BSET - Get Free Report) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a
Zepp Health (NYSE: ZEPP - Get Free Report) and Hovnanian Enterprises (NYSE: HOV - Get Free Report) are both small-cap consumer discretionary companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Profitability This table compares Zepp Health
Zepp Health Corporation (ZEPP) Q2 2026 Earnings Call Transcript
Zepp Health NYSE: ZEPP reported second-quarter 2026 revenue of $63.5 million, up 6.9% from a year earlier, as new product launches and a higher-priced product mix supported growth. Gross margin improved to 37.4% from 36.2% a year earlier despite higher memory and component costs, according to management.
Benchmark ZEPP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zepp Health Corporation (ZEPP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.25 | $2.23M | -0.05 | 36.12% | -15.64% | -27.93% | — | |
| $285.57 | $55.07B | 27.41 | 15.06% | 25.58% | 21.91% | 1.2% | |
| $7.81 | $461.58M | -6.59 | -12.28% | -7.09% | -82.2% | — | |
| $12.05 | $1.07B | -6.84 | -6.51% | -11.49% | -10.23% | — | |
| $342.37 | $5.03T | 37.90 | 15.06% | 27.6% | 127.61% | 0.31% | |
| $53.04 | $48.07B | 18.98 | 8.37% | 21.86% | 8.3% | 3.28% |
Zepp Health Corporation (ZEPP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ZEPP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zepp Health Corporation (ZEPP) stock FAQ — growth, dividends, profitability & financials explained
Zepp Health Corporation (ZEPP) reported $1.93B in revenue over the trailing twelve months. Revenue was $1.82B in fiscal year 2025. That is 96% more than the $925.4M of fiscal year 2015.
Zepp Health Corporation (ZEPP) grew revenue by 34.0% over the trailing twelve months, compared with the twelve months before.
No. Zepp Health Corporation (ZEPP) reported a net loss of $301.5M over the trailing twelve months.
Zepp Health Corporation (ZEPP) had a return on equity (ROE) of -27.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Zepp Health Corporation (ZEPP) had negative free cash flow of $185.1M over the trailing twelve months.
